Vitrolife AB

As of June 30, 2026, Vitrolife AB carries a market capitalization of 1.08B, placing it among publicly traded companies globally. Its enterprise value stands at 1.15B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Vitrolife AB's next confirmed earnings release is scheduled for October 22, 2026.

As of June 30, 2026, Vitrolife AB has 135.45M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.50, and the price-to-book ratio stands at 1.47.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.73 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.15B versus a market cap of 1.08B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Vitrolife AB maintains a current ratio of 3.64, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Vitrolife AB posted a negative return on equity (ROE) of -46.89, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -35.69, reflecting losses generated across the asset base. The company generates approximately 270,551.46 in revenue per employee across its workforce of 1,143.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.29 indicates how many times Vitrolife AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Vitrolife AB recorded 12.19M in income tax expense. The company reported a pretax loss of -437.78M and -449.97M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Vitrolife AB's stock has declined approximately 30.54% over the past 52 weeks. The 50-day moving average sits at 8.39, while the 200-day moving average is 8.93.

Over the twelve months ended June 30, 2026, Vitrolife AB generated 309.31M in revenue and converted that into -449.97M in net income, yielding earnings per share of -3.32. EBITDA reached -431.82M, while operating income came in at -431.82M.

As of June 30, 2026, Vitrolife AB holds 74.30M in cash and equivalents against 144.54M in total debt, resulting in a net debt position of 58.77M. Total book value stands at 734.18M, with working capital of 144.00M providing operational flexibility.

Vitrolife AB produced 56.25M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -12.10M in capital expenditures, free cash flow totaled 44.15M - equivalent to 0.33 per share.

Over the twelve months ended June 30, 2026, Vitrolife AB posted a gross margin of 59.02, reflecting its pricing power and cost economics. The operating margin of -139.61 and net profit margin of -145.48 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Vitrolife AB paid dividends of 0.20 per share. The dividend payout ratio of -5.98 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 4.08, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 6.26, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Vitrolife AB shareholders.

Vitrolife AB's most recent stock split took place on May 17, 2018 with a 1:5 split ratio.

As of June 30, 2026, Vitrolife AB has an Altman Z-Score of -4.34, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.